Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 1
Submit an article Journal homepage
99
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Immunization of Newborn and Adult Mice with Low Numbers of BCG Leads to Th1 Responses, Th1 Imprints and Enhanced Protection Upon BCG Challenge

Tadele G Kiros1 Vaccine & Infectious Diseases Organization, University of Saskatchewan, Canada. [email protected]View further author information
,
Carl A Power2 Prince Wales Hospital, Australia. [email protected]View further author information
,
Guojian Wei3 Western College of Veterinary Medicine, Canada. [email protected]View further author information
&
Peter A Bretscher4 Department of Microbiology & Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, S7N 5E5, Canada. Tel.: +1 306 966 4322 Fax: +1 306 966 [email protected]View further author information
Pages 25-35 | Published online: 17 Dec 2009

Bibliography

  • Trunz BB , FineP, DyeC: Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta- analysis and assessment of cost–effectiveness.Lancet367(9517) , 1173–1180 (2006).
  • Comstock GW , PalmerCE: Long-term results of BCG vaccination in the southern united states.Am. Rev. Respir. Dis.93(2) , 171–183 (1966).
  • Baily GV : Tuberculosis prevention trial, madras.Indian J. Med. Res.72(Suppl.) 1–74 (1980).
  • Hart PD , SutherlandI: BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life.Br. Med. J.2(6082) , 293–295 (1977).
  • Aronson NE , SantoshamM, ComstockGW et al.: Long-term efficacy of BCG vaccine in American–Indians and Alaska natives: a 60-year follow-up study.JAMA291(17) , 2086–2091 (2004).
  • Bretscher P , MenonJ, PowerC, UzonnaJ, WeiG: A case for a neonatal, low-dose BCG vaccination trial.Scand. J. Infect. Dis.33(4) , 253–257 (2001).
  • Rook GA : Th2 cytokines in susceptibility to tuberculosis.Curr. Mol. Med.7(3) , 327–337 (2007).
  • Demissie A , AbebeM, AseffaA et al.: Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4δ2.J. Immunol.172(11) , 6938–6943 (2004).
  • Ordway DJ , MartinsMS, CostaLM et al.: Increased IL-4 production in response to virulent Mycobacterium tuberculosis in tuberculosis patients with advanced disease.Acta Med. Port.18(1) , 27–36 (2005).
  • Lienhardt C , AzzurriA, AmedeiA et al.: Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo.Eur. J. Immunol.32(6) , 1605–1613 (2002).
  • Bretscher PA , IsmailN, MenonJN, PowerCA, UzonnaU, WeiW: Vaccination against and treatment of tuberculosis, the leishmaniasis and AIDS: perspectives from basic immunology and immunity to chronic intracellular infections.Cell. Mol. Life Sci.58 , 1879–1896 (2001).
  • Hamilton D , IsmailN, KroegerD, RudulierC, BretscherP: Macroimmunology and immunotherapy of cancer.Immunotherapy1(3) , 367–383 (2009).
  • Bretscher PA , WeiG, MenonJN, Bielefeldt-OhmannH: Establishment of stable, cell-mediated immunity that makes ‘susceptible‘ mice resistant to Leishmania major.Science257(5069) , 539–542 (1992).
  • Menon JN , BretscherPA: Characterization of the immunological memory state generated in mice susceptible to L. major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge.Eur. J. Immunol.26(1) , 243–249 (1996).
  • Murphy D , Corner La, Gormley E: Adverse reactions to Mycobacterium bovis bacille Calmette–Guerin (BCG) vaccination against tuberculosis in humans, veterinary animals and wildlife species. Tuberculosis (Edinb.)88(4) , 344–357 (2008).
  • Buddle BM , PollockJM, SkinnerMA, WedlockDN: Development of vaccines to control bovine tuberculosis in cattle and relationship to vaccine development for other intracellular pathogens.Int. J. Parasitol.33(5–6) , 555–566 (2003).
  • Buddle BM , De Lisle GW, Pfeffer A, Aldwell FE: Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG. Vaccine13(12) , 1123–1130 (1995).
  • Buddle BM , DenisM, AldwellFE, VordermeierMH, HewinsonGR, WedlockND: Vaccination of cattle with Mycobacterium bovis BCG by a combination of systemic and oral routes.Tuberculosis (Edinb.)88(6) , 595–600 (2008).
  • Power CA , WeiG, BretscherPA: Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route.Infect. Immun.66(12) , 5743–5750 (1998).
  • Young SL , SlobbeL, WilsonR, BuddleBM, De Lisle GW, Buchan GS: Environmental strains of Mycobacterium avium interfere with immune responses associated with Mycobacterium bovis BCG vaccination. Infect. Immun.75(6) , 2833–2840 (2007).
  • Adkins B , BuY, VincekV, GuevaraP: The primary responses of murine neonatal lymph node CD4+ cells are Th2-skewed and are sufficient for the development of Th2-biased memory.Clin. Dev. Immunol.10(1) , 43–51 (2003).
  • Barrios C , BrawandP, BerneyM, BrandtC, LambertPH, SiegristCA: Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting.Eur. J. Immunol.26(7) , 1489–1496 (1996).
  • Gros P , SkameneE, ForgetA: Genetic control of natural resistance to Mycobacterium bovis(BCG) in mice.J. Immunol.127(6) , 2417–2421 (1981).
  • North RJ , JungYJ: Immunity to tuberculosis.Annu. Rev. Immunol.22 , 599–623 (2004).
  • Bretscher PA : In vitro induction of delayed-type hypersensitivity.Eur. J. Immunol.9(4) , 311–316 (1979).
  • Power CA , GrandCL, IsmailN, PetersNC, YurkowskiDP, BretscherPA: A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFN-γ-producing T cells.J. Immunol. Methods227(1–2) , 99–107 (1999).
  • Taguchi T , McgheeJR, CoffmanRL et al.: Detection of individual mouse splenic T cells producing IFN-γ and IL-5 using the enzyme-linked immunospot (ELISPOT) assay.J. Immunol. Methods128(1) , 65–73 (1990).
  • Kiros TG : Low dose BCG vaccination in mice: immune responses and implications for tuberculosis control. Department of Microbiology and Immunology. University of Saskatchewan, Canada. PhD thesis, 250 (2007).
  • Xiao SY , LiY, ChenWF: Kinetics of thymocyte developmental process in fetal and neonatal mice.Cell. Res.13(4) , 265–273 (2003).
  • Siegrist CA : The challenges of vaccine responses in early life: selected examples.J. Comp. Pathol.137(Suppl. 1) , S4–S9 (2007).
  • Marchant A , GoetghebuerT, Ota Mo et al.: Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette–Guerin vaccination. J. Immunol.163(4) , 2249–2255 (1999).
  • Soares AP , ScribaTJ, JosephS et al.: Bacillus Calmette–Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles.J. Immunol.180(5) , 3569–3577 (2008).
  • Cooper AM , MagramJ, FerranteJ, OrmeIM: Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis.J. Exp. Med.186(1) , 39–45 (1997).
  • Gardam MA , KeystoneEC, MenziesR et al.: Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.Lancet Infect. Dis.3(3) , 148–155 (2003).
  • Flynn JL , ChanJ, TrieboldKJ, DaltonDK, StewartTA, BloomBR: An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection.J. Exp. Med.178(6) , 2249–2254 (1993).
  • Ottenhoff TH , De Boer T, Van Dissel JT, Verreck FA: Human deficiencies in type-1 cytokine receptors reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Adv. Exp. Med. Biol.531 , 279–294 (2003).
  • Sarzotti M , RobbinsDS, Hoffman Pm: Induction of protective CTL responses in newborn mice by a murine retrovirus. Science271(5256) , 1726–1728 (1996).
  • Fadel SA , OzakiDA, SarzottiM: Enhanced type 1 immunity after secondary viral challenge in mice primed as neonates.J. Immunol.169(6) , 3293–3300 (2002).
  • Steinman L : A brief history of Th17, the first major revision in the Th1/Th2 hypothesis of t cell-mediated tissue damage.Nat. Med.13(2) , 139–145 (2007).
  • Curtis MM , WaySS: Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens.Immunology126(2) , 177–185 (2009).
  • Khader SA , CooperAM: IL-23 and IL-17 in tuberculosis.Cytokine41(2) , 79–83 (2008).
  • Cooper AM , DaltonDK, StewartTA, GriffinJP, RussellDG, OrmeIM: Disseminated tuberculosis in interferon γ gene-disrupted mice.J. Exp. Med.178(6) , 2243–2247 (1993).
  • Jouanguy E , AltareF, LamhamediS et al.: Interferon-γ-receptor deficiency in an infant with fatal bacille Calmette–Guerin infection.N. Engl. J. Med.335(26) , 1956–1961 (1996).
  • Doffinger R , DupuisS, PicardC et al.: Inherited disorders of IL-12- and IFN-γ-mediated immunity: a molecular genetics update.Mol. Immunol.38(12–13) , 903–909 (2002).
  • Brandt L , Feino Cunha J, Weinreich Olsen A et al.: Failure of the Mycobacterium bovi s BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun.70(2) , 672–678 (2002).
  • Buddle BM , WardsBJ, AldwellFE, CollinsDM, De Lisle GW: Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine20(7–8) , 1126–1133 (2002).
  • Weir RE , BlackGF, NazarethB et al.: The influence of previous exposure to environmental mycobacteria on the interferon-g response to bacille Calmette–Guerin vaccination in southern England and northern Malawi.Clin. Exp. Immunol.146(3) , 390–399 (2006).
  • Hernandez-Pando R , PavonL, ArriagaK, OrozcoH, Madrid-MarinaV, RookG: Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection.Infect. Immun.65(8) , 3317–3327 (1997).
  • Horwitz MA , HarthG, DillonBJ, Maslesa-GalicS: Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity.Vaccine24(4) , 443–451 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.